Important Safety Information

• Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
• Epinephrine and other appropriate agents used for control of immediate allergic reactions must be immediately available should an acute hypersensitivity or anaphylactic reaction occur following the administration of BOOSTRIX
• The tip caps of the prefilled syringes for BOOSTRIX contain natural rubber latex, which may cause allergic reactions
• The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
• Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
• Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

Following an initial vaccination with BOOSTRIX

• Common solicited adverse reactions (≥15%) in adolescents (aged 10 to 18 years) were pain, redness, and swelling at the injection site; increase in arm circumference of the injected arm; headache; fatigue; and gastrointestinal symptoms
• Common solicited adverse reactions (≥15%) in adults (aged 19 to 64 years) were pain, redness, and swelling at the injection site; headache; fatigue; and gastrointestinal symptoms
• The most common solicited adverse reaction (≥15%) in the elderly (aged 65 years and older) was pain at the injection site

Following revaccination with BOOSTRIX

• Common solicited adverse reactions (≥15%) in adults (aged 20 years and older) were pain, redness, and swelling at the injection site; headache; and fatigue.

Vaccination with BOOSTRIX may not result in protection in all vaccine recipients

Please see full Prescribing Information for BOOSTRIX.